Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Wang, Xiao ^a   Wang, Xinghuan ^a   Liu, Tao ^a   He, Qianwen ^a   Wang, Yipeng ^a   Zhang, Xinhua ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL;

ADVERSE OUTCOME; ARTICLE; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; ERECTILE DYSFUNCTION; GLOBAL ASSESSMENT QUESTION; HEADACHE; HUMAN; INCIDENCE; INTERNATIONAL INDEX OF ERECTILE FUNCTION; META ANALYSIS; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SEXUAL ENCOUNTER PROFILE; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; MALE; RISK; TREATMENT OUTCOME;

ERECTILE DYSFUNCTION; HUMANS; MALE; ODDS RATIO; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84897474528     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091327     Document Type: Article

References (40)

1. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488. (Pubitemid 40458328)
2. Montorsi F, McCullough A (2005) Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med 2: 658-667. (Pubitemid 41742926)
3. Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, et al. (2005) Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol 174: 646-650. (Pubitemid 40981623)
4. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, et al. (2004) Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 172: 2227-2231. (Pubitemid 39507497)
5. Lee R, Penson DF (2002) Treatment outcomes in localized prostate cancer: a patient-oriented approach. Semin Urol Oncol 20: 63-73. (Pubitemid 34132327)
6. Zippe CD, Raina R, Thukral M, Lakin MM, Klein EA et al. (2001) Management of erectile dysfunction following radical prostatectomy. Curr Urol Rep 2: 495-503.
7. Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer J (2008) Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review. Int J Impot Res 20: 30-34.
8. Catalona WJ, Basler JW (1993) Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol 150: 905-907. (Pubitemid 23241296)
9. Geary ES, Dendinger TE, Freiha FS, Stamey TA (1995) Nerve sparing radical prostatectomy: a different view. J Urol 154: 145-149.
10. Quinlan DM, Epstein JI, Carter BS, Walsh PC (1991) Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 145: 998-1002.
11. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT (2000) Factors predicting recovery of erections after radical prostatectomy. J Urol 164: 1929-1934.
12. Walsh PC (1987) Radical prostatectomy, preservation of sexual function, cancer control. The controversy. Urol Clin North Am 14: 663-673.
13. Tutolo M, Briganti A, Suardi N, Gallina A, Abdollah F, et al. (2012) Optimizing postoperative sexual function after radical prostatectomy. Ther Adv Urol 4: 347-365.
14. Mulhall JP, Graydon RJ (1996) The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Int J Impot Res 8: 91-94.
15. Wang R (2007) Penile rehabilitation after radical prostatectomy: where do we stand and where are we going? J Sex Med 4: 1085-1097.
16. User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT (2003) Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 169: 1175-1179. (Pubitemid 36188196)
17. Klein LT, Miller MI, Buttyan R, Raffo AJ, Burchard M, et al. (1997) Apoptosis in the rat penis after penile denervation. J Urol 158: 626-630. (Pubitemid 27327736)
18. Raina R, Pahlajani G, Agarwal A, Zippe CD (2008) Early penile rehabilitation following radical prostatectomy: Cleveland clinic experience. Int J Impot Res 20: 121-126. (Pubitemid 351374319)
19. Zippe CD, Pahlajani G (2007) Penile rehabilitation following radical prostatectomy: role of early intervention and chronic therapy. Urol Clin North Am 34: 601-18, viii. (Pubitemid 350029952)
20. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, et al. (2007) Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 178: 597-601. (Pubitemid 47030514)
21. Briganti A, Montorsi F (2006) Penile rehabilitation after radical prostatectomy. Nat Clin Pract Urol 3: 400-401. (Pubitemid 44226911)
22. Mulhall JP (2009) The role and structure of a postradical prostatectomy penile rehabilitation program. Curr Urol Rep 10: 219-225.
23. Hatzimouratidis K, Hatzichristou D (2007) Phosphodiesterase type 5 inhibitors: the day after. Eur Urol 51: 75-88.
24. Giuliano F, Amar E, Chevallier D, Montaigne O, Joubert JM, et al. (2008) How urologists manage erectile dysfunction after radical prostatectomy: a national survey (REPAIR) by the French urological association. J Sex Med 5: 448-457. (Pubitemid 351167753)
25. Montorsi F, Brock G, Lee J, Shapiro J, Van PH, et al. (2008) Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 54: 924-931.
26. Aydogdu O, Gokce MI, Burgu B, Baltaci S, Yaman O (2011) Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy. Int Braz J Urol 37: 336-344.
27. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, et al. (2008) Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 20: 479-486.
28. Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, et al. (2003) Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 170: 1278-1283. (Pubitemid 37108132)
29. Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G, et al. (2004) Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 172: 1036-1041. (Pubitemid 39096457)
30. Mulhall JP, Burnett AL, Wang R, McVary KT, Moul JW, et al. (2013) A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. J Urol 189: 2229-2236.
31. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP (2008) Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 101: 1279-1283. (Pubitemid 351549634)
32. Cavallini G, Modenini F, Vitali G, Koverech A (2005) Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 66: 1080-1085. (Pubitemid 41587165)
33. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, et al. (1997) Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 158: 1408-1410.
34. Magheli A, Burnett AL (2009) Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol 6: 415-427.
35. Candy B, Jones L, Williams R, Tookman A, King M (2008) Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review. BJU Int 102: 426-431. (Pubitemid 352032841)
36. Padma-nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F (2002) A 4-year update on the safety of sildenafil citrate (Viagra). Urology 60: 67-90. (Pubitemid 35303364)
37. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, et al. (2004) The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. Eur Urol 45: 634-641. (Pubitemid 38481692)
38. Jackson G, Kloner RA, Costigan TM, Warner MR, Emmick JT (2004) Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 1: 161-167. (Pubitemid 40424649)
39. Takimoto E, Champion HC, Li M, Belardi D, Ren S, et al. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214-222. (Pubitemid 40321358)
40. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA (2005) Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 112: 2642-2649. (Pubitemid 41532601)